Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says

Published 02/28/2024, 05:57 AM
Updated 02/28/2024, 07:21 AM
© Reuters. FILE PHOTO: A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo

By Rishika Sadam and Leroy Leo

HYDERABAD (Reuters) -U.S. drugmaker Eli Lilly (NYSE:LLY) expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday.

The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are testing their own versions of weight-loss drugs, while illegal versions are also sold online.

"Our famous Mounjaro – it's under review now. So, perhaps as early as next year to the Indian market," Ricks told Reuters on the sidelines of the BioAsia conference in the southern state of Telangana.

When asked about potentially partnering with others to bring the drug to the market, Ricks said the U.S. drugmaker was "open to any way to reach more patients as long as it makes sense for the company and we can supply the market."

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions. However, it is sold under the brand name Zepbound for weight loss in the U.S.

Mounjaro is being reviewed by Indian drug regulators, for which Lilly is using data from its global trials, which included some Indian participants, a company source said, declining to be named as they are not authorized to speak to the media.

Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk (NYSE:NVO)'s in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, developed to control blood sugar in patients with type 2 diabetes.

But they also slow digestion, helping patients feel full longer, which has led to an explosion in their popularity and left Lilly and Novo Nordisk struggling to keep up with demand.

The global market for these treatments is expected to reach at least $100 billion by the end of the decade, analysts estimate.

Last year, a top Novo Nordisk official told Reuters the Danish company was aiming to bring Wegovy to India in 2026.

Indian drugmakers, which are among the world's largest generic drug makers, are already developing their own versions of Wegovy.

These companies include Zydus Lifesciences, Sun Pharma, Cipla, Dr Reddy's and Lupin.

Of them, Lupin and Cipla are Lilly's Indian distributors, including for some of its older diabetes treatments such as Eglucent, Aplevant, Basaglar and Trulicity.


India should boost patent protection, get rid of redundant policies and create a social safety net to win more investment from global drugmakers, Ricks said in his keynote address at the BioAsia conference.

These steps, he said, would help drive "broader interests for multinationals and foreign direct investment" in India's pharmaceutical industry.

© Reuters. FILE PHOTO: A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo

"India has many specific policies related to its regulatory environment all set up for good reason. But in hindsight, perhaps we can reflect upon them and find redundant policies that only cause delay and extra cost."

Ricks said these regulatory challenges had the "two-way effect" of making it tough for companies like Lilly to bring new medicines into the market and constraining local biotechs to export their inventions.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.